175 related articles for article (PubMed ID: 37187730)
1. Identification of calcium and integrin-binding protein 1 as a reprogrammed glucose metabolism mediator to restrict immune cell infiltration in the stromal compartment of pancreatic ductal adenocarcinoma.
Ma J; Song Y; Zhuang T; Yang H; Yang X; Zheng J; Luo J; Xia Y; Fei X; Chan DW; Wu D; Xu P; Ni P; Dai J; Xu D; Hu Y
Front Immunol; 2023; 14():1158964. PubMed ID: 37187730
[TBL] [Abstract][Full Text] [Related]
2. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
3. Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma.
Liu YH; Hu CM; Hsu YS; Lee WH
Cell Death Dis; 2022 Sep; 13(9):817. PubMed ID: 36151074
[TBL] [Abstract][Full Text] [Related]
4. Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study.
Yang F; He Y; Ge N; Guo J; Yang F; Sun S
Front Immunol; 2023; 14():1203459. PubMed ID: 38268915
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.
Ijichi H; Chytil A; Gorska AE; Aakre ME; Bierie B; Tada M; Mohri D; Miyabayashi K; Asaoka Y; Maeda S; Ikenoue T; Tateishi K; Wright CV; Koike K; Omata M; Moses HL
J Clin Invest; 2011 Oct; 121(10):4106-17. PubMed ID: 21926469
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitin-Specific Protease 43 Impacts Pancreatic Ductal Adenocarcinoma Prognosis by Altering Its Proliferation and Infiltration of Surrounding Immune Cells.
Zhao Z; Lin Z; Guo X; Al-Danakh A; He H; Qin H; Ma C; Zhang N; Tan G
J Immunol Res; 2023; 2023():4311388. PubMed ID: 37050932
[TBL] [Abstract][Full Text] [Related]
7. Zeb1 in Stromal Myofibroblasts Promotes
Sangrador I; Molero X; Campbell F; Franch-Expósito S; Rovira-Rigau M; Samper E; Domínguez-Fraile M; Fillat C; Castells A; Vaquero EC
Cancer Res; 2018 May; 78(10):2624-2637. PubMed ID: 29490942
[TBL] [Abstract][Full Text] [Related]
8. Targeting ONECUT3 blocks glycolytic metabolism and potentiates anti-PD-1 therapy in pancreatic cancer.
Chen PC; Ning Y; Li H; Su JG; Shen JB; Feng QC; Jiang SH; Shi PD; Guo RS
Cell Oncol (Dordr); 2024 Feb; 47(1):81-96. PubMed ID: 37606818
[TBL] [Abstract][Full Text] [Related]
9. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma.
Ene-Obong A; Clear AJ; Watt J; Wang J; Fatah R; Riches JC; Marshall JF; Chin-Aleong J; Chelala C; Gribben JG; Ramsay AG; Kocher HM
Gastroenterology; 2013 Nov; 145(5):1121-32. PubMed ID: 23891972
[TBL] [Abstract][Full Text] [Related]
10. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
11. Multidimensional screening of pancreatic cancer spheroids reveals vulnerabilities in mitotic and cell-matrix adhesion signaling that associate with metastatic progression and decreased patient survival.
Aquino AF; Runa F; Shoma JF; Todd A; Wallace M; de Barros NR; Kelber JA
Biochem Biophys Res Commun; 2024 Apr; 703():149575. PubMed ID: 38382357
[TBL] [Abstract][Full Text] [Related]
12. Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment.
Pu N; Chen Q; Gao S; Liu G; Zhu Y; Yin L; Hu H; Wei L; Wu Y; Maeda S; Lou W; Yu J; Wu W
Ann Transl Med; 2019 Nov; 7(22):645. PubMed ID: 31930046
[TBL] [Abstract][Full Text] [Related]
13. Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.
Hosein AN; Dangol G; Okumura T; Roszik J; Rajapakshe K; Siemann M; Zaid M; Ghosh B; Monberg M; Guerrero PA; Singhi A; Haymaker CL; Clevers H; Abou-Elkacem L; Woermann SM; Maitra A
Gastroenterology; 2022 Apr; 162(4):1303-1318.e18. PubMed ID: 34973294
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer.
Humpton TJ; Alagesan B; DeNicola GM; Lu D; Yordanov GN; Leonhardt CS; Yao MA; Alagesan P; Zaatari MN; Park Y; Skepper JN; Macleod KF; Perez-Mancera PA; Murphy MP; Evan GI; Vousden KH; Tuveson DA
Cancer Discov; 2019 Sep; 9(9):1268-1287. PubMed ID: 31263025
[TBL] [Abstract][Full Text] [Related]
15. Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma.
Luan H; Zhang C; Zhang T; He Y; Su Y; Zhou L
Dis Markers; 2020; 2020():8825997. PubMed ID: 32934754
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity for Kras
Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
[TBL] [Abstract][Full Text] [Related]
17. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
18. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
19. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma.
Murakami S; Shahbazian D; Surana R; Zhang W; Chen H; Graham GT; White SM; Weiner LM; Yi C
Oncogene; 2017 Mar; 36(9):1232-1244. PubMed ID: 27546622
[TBL] [Abstract][Full Text] [Related]
20. IRAK2-NF-κB signaling promotes glycolysis-dependent tumor growth in pancreatic cancer.
Yang J; Liu DJ; Zheng JH; He RZ; Xu DP; Yang MW; Yao HF; Fu XL; Yang JY; Huo YM; Tao LY; Hua R; Sun YW; Kong XM; Jiang SH; Liu W
Cell Oncol (Dordr); 2022 Jun; 45(3):367-379. PubMed ID: 35486320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]